Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (final guidance)
23 October 2024 - NICE has published final evidence-based recommendations on the use of danicopan (Voydeya) in combination with ravulizumab ...
Posted by Michael Wonder on 17 Oct 2024
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
17 October 2024 - For the first time, NICE has recommended a targeted treatment option for ALK positive non-small-cell lung cancer, ...
Posted by Michael Wonder on 17 Oct 2024
Eplontersen approved to treat adults with rare inherited nerve disease or polyneuropathy
16 October 2024 - The MHRA has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis, which ...
Posted by Michael Wonder on 09 Oct 2024
Elafibranor approved as first medicine to treat adults with a rare liver disease known as primary biliary cholangitis
8 October 2024 - The MHRA has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease ...
Posted by Michael Wonder on 09 Oct 2024
MHRA launches 2024/25 business plan with focus on enabling access to groundbreaking new technology while optimising delivery for all who need our services
7 October 2024 - The MHRA has today launched its ambitious new business plan for 2024/25, setting out the agency’s core ...
Posted by Michael Wonder on 08 Oct 2024
Fruquintinib for patients with previously treated metastatic colorectal cancer
8 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2024
Bimekizumab for the treatment of patients with moderate to severe hidradenitis suppurativa
7 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Oct 2024
Consultation on NHS England proposals for a phased launch of obesity injection
3 October 2024 - Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation ...
Posted by Michael Wonder on 04 Oct 2024
Netarsudil mesylate with latanoprost for the treatment of patients with primary open-angle glaucoma or ocular hypertension
2 October 2024 - NiCE has published final evidence-based recommendations on the use of netarsudil mesylate with latanoprost (Roclanda) for ...
Posted by Michael Wonder on 02 Oct 2024
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, ESR1 mutation positive, HER2 negative breast cancer after at least one endocrine treatment
1 October 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 02 Oct 2024
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of ...
Posted by Michael Wonder on 29 Sep 2024
Cabotegravir for the prevention of HIV-1 infection in adults and adolescents
26 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 22 Sep 2024
Fruquintinib approved to treat adult patients with metastatic colorectal cancer
20 September 2024 - The MHRA has today approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal ...
Posted by Michael Wonder on 20 Sep 2024
Fosdenopterin hydrobromide for the treatment of patients molybdenum cofactor deficiency type A
19 September 2024 - The Department of Health and Social Care has NICE to produce guidance on the use of ...